Advertisement

Topics

Biogen Idec Company Profile

03:11 EST 16th December 2018 | BioPortfolio

Scientific excellence that achieves new standards of care drives the company's work. 17 products are currently in clinical development addressing a variety of key medical needs.With patients in more than 90 countries, two blockbuster drugs lead Biogen Idec's product lineup:RITUXAN® (rituximab) was discovered by Biogen Idec for the treatment of certain B-cell non-Hodgkin's lymphomas (NHL). The company co-promotes the product in the United States with Genentech, Inc. In 2005, RITUXAN generated U.S. net sales of $1.8 billion of which Biogen Idec recorded $709 million as co-promotion profits.AVONEX® (Interferon beta 1-a) is indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS) and is the most prescribed product in MS worldwide with close to 130,000 patients on therapy. In 2005, sales of AVONEX generated worldwide revenues of $1.54 billion.

Location

14 Cambridge Center
Cambridge
02142
United States of America

Contact

Phone: (617) 679-2000
Fax: 617-679-2617


News Articles [448 Associated News Articles listed on BioPortfolio]

Creating an urgency to change. Mikael Nilsson, Director of Marketing Excellence, Biogen Idec

Of the 20 to 60 thousand thoughts we have per day only about 2% are new. Most of our thoughts are old thoughts and that tells us something about the challenge to change. During the eyeforpharma confe...

Nomura wertet Biogen-Studie zu Alzheimer-Wirkstoff psoitiv

Das japanische Analysehaus Nomura hat die Einstufung für Biogen Idec nach positiven Daten zum Wirkstoff BAN2401 gegen Alzheimer auf "Buy" mit einem Kursziel von 420 US-Dollar belassen. Mit den Erg...

Pooled analysis results of adalimumab, etanercept and infliximab biosimilars

South Korean electronics giant Samsung and biotechnology company Biogen Idec (Biogen) joint venture Samsung Bioepis, along with Biogen, announced on 13 June 2018 results of a pooled analysis combining...

Biogen, Inc. Strategy, SWOT and Corporate Finance Report [Report Updated: 28082018] Prices from USD $175

Biogen, Inc. Strategy, SWOT and Corporate Finance ReportSummaryBiogen, Inc. Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers ...

STAT Plus: Here’s why Biogen lost $7 billion overnight despite ‘positive’ Alzheimer’s data

The latest Alzheimer's data from Biogen and its partner Eisai have renewed hopes for an effective treatment. So why has Biogen's stock tanked?

MSD signs $117m deal with Samsung Bioepis over Janssen biosimilar

American multinational MSD have won a $117 million contract allowing them to supply Samsung Bioepis’ Renflexis to the US Department of Veteran Affairs. The deal between the multibillion dollar pharm...

Trading-Idee Biogen: Beachtenswertes Biotechnologie-Unternehmen

Biogen ist ein beachtenswertes Biotechnologie-Unternehmen. Daher kommt man im Bereich der Neurowissenschaften um Biogen nicht herum. Insbesondere mit seiner Spezialisierung auf Erkrankungen der Ner...

Biogen Inc.: IMRALDI, Biogen's Adalimumab Biosimilar Referencing Humira, Is Launched in the European Union

IMRALDITM is approved in the European Union for the same 14 complex autoimmune conditions as its reference product In 2017 Biogen became the first company in Europe with approved biosimilars refere...

Drugs and Medications [4 Associated Drugs and Medications listed on BioPortfolio]

Avonex [Biogen Idec MA Inc.]

AVONEX (Interferon beta-1a)IM Injection

Avonex [Biogen Idec MA Inc.]

AVONEX (Interferon beta-1a)IM Injection

Indium in 111 chloride [Mallinckrodt Inc.]

Indiclorhigh purity indium chloride in-111 sterile solution [Amersham Health]

INDICLORHigh Purity Indium Chloride In-111 Sterile Solution

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

A Review on Clinical Pharmacokinetics, Pharmacodynamics, and pharmacogenomics of natalizumab: A Humanized Anti-α4 Integrin Monoclonal Antibody.

Natalizumab (Tysabri®, Biogen-Idec Inc., NAT), a humanized anti-α4 integrin monoclonal antibody, binds in both α4β1 (Very Late Antigen 4, VLA-4) and α4β7 (lymphocytes Peyer's patch adhesion mole...

Clinical Trials [11 Associated Clinical Trials listed on BioPortfolio]

Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma

This is a Phase I/II open-label, dose-escalating study in patients with metastatic colorectal cancer. The objectives of the study are to obtain information on the safety of radiolabeled I...

Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma

The purpose of this study is to determine whether anti-CD80 monoclonal antibody (IDEC-114) is effective in the treatment of follicular B-cell non-Hodgkin's lymphoma. This drug has never b...

Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma

To determine what side effects and what clinical effect, if any, the administration of this investigational product, IDEC-114 in combination with Rituxan® [Rituxan® as a single agent is ...

ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.

The purpose of this study is to see if we can find a new way to test how certain Multiple Sclerosis (MS) medications work in the body and to better understand how the medicines change cert...

Pregnancy Exposure Registry for AVONEX

This is an observational, exposure-registration and follow-up study, which will be conducted in the United States (US). The AVONEX® Pregnancy Exposure Registry is designed to monitor pre...

Companies [34 Associated Companies listed on BioPortfolio]

Biogen Idec Inc.

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufa...

Biogen Idec and Elan Corporation, plc

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufa...

Biogen Idec and Abbott

Biogen Idec uses cutting-edge science to discover, develop, manufacture and market therapies for serious diseases with a focus on neurology, immunology and hemophilia. Founded in ...

Biogen Idec and Portola Pharmaceuticals

Biogen Idec uses cutting-edge science to discover, develop, manufacture and market therapies for serious diseases with a focus on neurology, immunology and hemophilia. Founded in ...

Biogen Idec

Scientific excellence that achieves new standards of care drives the company's work. 17 products are currently in clinical development addressing a variety of key medical needs.With patients in more t...

More Information about "Biogen Idec" on BioPortfolio

We have published hundreds of Biogen Idec news stories on BioPortfolio along with dozens of Biogen Idec Clinical Trials and PubMed Articles about Biogen Idec for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Biogen Idec Companies in our database. You can also find out about relevant Biogen Idec Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...


Corporate Database Quicklinks



Searches Linking to this Company Record